Experienced in Neurofibromatosis Type 1 (NF1)

Dr. Eric T. Wong

Neurology
Rhode Island Hospital
593 Eddy St, Apc 138, 
Providence, RI 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Neurofibromatosis Type 1 (NF1)
Rhode Island Hospital
593 Eddy St, Apc 138, 
Providence, RI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Eric Wong is a Neurologist in Providence, Rhode Island. Dr. Wong is rated as an Experienced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Craniectomy.

His clinical research consists of co-authoring 151 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in MA
Hospital Affiliations
Rhode Island Hospital
The Miriam Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

RHODE ISLAND HOSPITAL
593 Eddy St, Apc 138, Providence, RI 02903

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase Ib/II Study of Pembrolizumab, Ibrutinib and Rituximab in Refractory/Relapsed Primary Central Nervous System Lymphoma (PCNSL)
A Phase Ib/II Study of Pembrolizumab, Ibrutinib and Rituximab in Refractory/Relapsed Primary Central Nervous System Lymphoma (PCNSL)
Enrollment Status: Recruiting
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drugs: Ibrutinib, Pembrolizumab, Rituximab
Study Phase: Phase 1/Phase 2
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Montanide ISA 51 VG, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide
Study Phase: Phase 2
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Combination product, Procedure, Drug
Study Drugs: IGV-001 Cell Immunotherapy, Temozolomide
Study Phase: Phase 2
Phase I and II Study of NovoTTF-200A and Pembrolizumab in Newly Diagnosed Melanoma Brain Metastasis
Phase I and II Study of NovoTTF-200A and Pembrolizumab in Newly Diagnosed Melanoma Brain Metastasis
Enrollment Status: Not_yet_recruiting
Publish Date: August 15, 2025
Intervention Type: Drug, Device
Study Drug: Pembrolizumab
Study Phase: Phase 1/Phase 2
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, Bevacizumab
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
View 6 Less Clinical Trials

151 Total Publications

Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM.
Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM.
Journal: Cancer immunology, immunotherapy : CII
Published: August 15, 2025
Similar Doctors
Elite in Neurofibromatosis Type 1 (NF1)
Dr. Scott R. Plotkin
Neurology
Elite in Neurofibromatosis Type 1 (NF1)
Dr. Scott R. Plotkin
Neurology

Mass General Brigham Cancer Institute: Neuro-Oncology

55 Fruit Street, Yawkey Center For Outpatient Care, 
Boston, MA 
 (41.9 miles away)
857-367-1486
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Plotkin is a Neurologist in Boston, Massachusetts. Dr. Plotkin is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis, and Acoustic Neuroma. Dr. Plotkin is currently accepting new patients.

Elite in Neurofibromatosis Type 1 (NF1)
Dr. Justin Jordan
Neurology
Elite in Neurofibromatosis Type 1 (NF1)
Dr. Justin Jordan
Neurology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (41.9 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Justin Jordan is a Neurologist in Boston, Massachusetts. Dr. Jordan is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Schwannomatosis, Neurofibromatosis, Neurofibromatosis Type 1 (NF1), and Neurofibromatosis Type 2 (NF2).

Elite in Neurofibromatosis Type 1 (NF1)
Dr. Nicole Ullrich
Pediatric Neurology | Neurology
Elite in Neurofibromatosis Type 1 (NF1)
Dr. Nicole Ullrich
Pediatric Neurology | Neurology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (39.5 miles away)
617-632-3586
Languages Spoken:
English
See accepted insurances

Nicole Ullrich is a Pediatric Neurologist and a Neurologist in Boston, Massachusetts. Dr. Ullrich is rated as an Elite provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). Her top areas of expertise are Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Schwannomatosis, and Optic Glioma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wong's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 9 Advanced Conditions
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile